Literature DB >> 1523478

Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients.

P Laothavorn1, J Karbwang, K Na Bangchang, D Bunnag, T Harinasuta.   

Abstract

Asymptomatic sinus bradycardia and sinus arrhythmia have been noted in malarial patients receiving mefloquine. The present study was designed to assess the effect of mefloquine on electrocardiogram in malarial patients. The study was carried out in 102 acute uncomplicated falciparum malarial patients who were treated with mefloquine 750 mg and 1,250 mg regimens and 18 healthy male volunteers receiving 750 mg of mefloquine. Electrocardiogram was performed at intervals after mefloquine administration for a period of 42 days. PR, QRS, QT, QTc, RR interval and cardiac arrhythmia were measured and read by EKG-analyser with confirmation by a cardiologist. Sinus bradycardia and sinus arrhythmia were found in 61.8% and 45.1%, respectively during the first week after treatment. The patients' heart rate decreased significantly on day 6 after mefloquine administration when compared to day 0. The occurrence of sinus bradycardia and sinus arrhythmia were significantly higher in malarial patients when compared with findings in healthy subjects of the same age group. It is unlikely that these changes are associated with mefloquine concentration as mefloquine peaks around 12-24 hours after administration. There were no significant changes in PR-interval, QRS-interval and QTc interval on the electrocardiogram. The findings in this study suggest that cardiotoxicity from mefloquine is unlikely. Bradycardia may be the result of autonomic control modulation after resolution of high fever.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1523478

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  8 in total

1.  Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine.

Authors:  I D Lightbown; J P Lambert; G Edwards; S J Coker
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.

Authors:  S Krudsood; S Looareesuwan; N Tangpukdee; P Wilairatana; W Phumratanaprapin; W Leowattana; K Chalermrut; S Ramanathan; V Navaratnam; P Olliaro; M Vaillant; J R Kiechel; W R J Taylor
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Effects of mefloquine on cardiac contractility and electrical activity in vivo, in isolated cardiac preparations, and in single ventricular myocytes.

Authors:  S J Coker; A J Batey; I D Lightbown; M E Díaz; D A Eisner
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 4.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

5.  Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients.

Authors:  F O ter Kuile; F Nosten; C Luxemburger; D Kyle; P Teja-Isavatharm; L Phaipun; R Price; T Chongsuphajaisiddhi; N J White
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

6.  Effects of anti-malarial drugs on the electrocardiographic QT interval modelled in the isolated perfused guinea pig heart system.

Authors:  Atsushi Kinoshita; Harumi Yamada; Hajime Kotaki; Mikio Kimura
Journal:  Malar J       Date:  2010-11-10       Impact factor: 2.979

7.  Physiologic regulation of heart rate and blood pressure involves connexin 36-containing gap junctions.

Authors:  Varinder K Lall; Gareth Bruce; Larysa Voytenko; Mark Drinkhill; Kerstin Wellershaus; Klaus Willecke; Jim Deuchars; Susan A Deuchars
Journal:  FASEB J       Date:  2017-05-22       Impact factor: 5.191

8.  The anti-malarial drug Mefloquine disrupts central autonomic and respiratory control in the working heart brainstem preparation of the rat.

Authors:  Varinder K Lall; Mathias Dutschmann; Jim Deuchars; Susan A Deuchars
Journal:  J Biomed Sci       Date:  2012-12-15       Impact factor: 8.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.